MX9304435A - Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii. - Google Patents

Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.

Info

Publication number
MX9304435A
MX9304435A MX9304435A MX9304435A MX9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A
Authority
MX
Mexico
Prior art keywords
treatment
prophylaxis
composition
obesity
diabetes
Prior art date
Application number
MX9304435A
Other languages
English (en)
Spanish (es)
Inventor
Barbara Anne Spicer
Kathryn Gay Ellis
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9304435A publication Critical patent/MX9304435A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9304435A 1992-07-23 1993-07-22 Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii. MX9304435A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929215633A GB9215633D0 (en) 1992-07-23 1992-07-23 Novel treatment

Publications (1)

Publication Number Publication Date
MX9304435A true MX9304435A (es) 1994-04-29

Family

ID=10719151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304435A MX9304435A (es) 1992-07-23 1993-07-22 Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.

Country Status (9)

Country Link
EP (1) EP0651642A1 (en:Method)
JP (1) JPH07509456A (en:Method)
CN (1) CN1043610C (en:Method)
AU (1) AU4714393A (en:Method)
GB (1) GB9215633D0 (en:Method)
MX (1) MX9304435A (en:Method)
TW (1) TW258663B (en:Method)
WO (1) WO1994002150A1 (en:Method)
ZA (1) ZA935339B (en:Method)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783408A (en) * 1995-06-07 1998-07-21 Hamilton; Bradford S. Method for screening potential anti-obesity agents
EP1953162B9 (de) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
WO2003004496A1 (en) * 2001-07-03 2003-01-16 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
US6869947B2 (en) 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1463727A2 (en) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7776893B2 (en) 2003-09-05 2010-08-17 Nycomed Gmbh Use of PDE4 inhibitors for the treatment of diabetes mellitus
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
WO2006094933A1 (en) 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2016079A1 (de) 2006-05-04 2009-01-21 Boehringer Ingelheim International GmbH Polymorphe
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
JP2013512229A (ja) 2009-11-27 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds

Also Published As

Publication number Publication date
CN1043610C (zh) 1999-06-16
CN1114880A (zh) 1996-01-17
ZA935339B (en) 1995-01-18
JPH07509456A (ja) 1995-10-19
WO1994002150A1 (en) 1994-02-03
AU4714393A (en) 1994-02-14
EP0651642A1 (en) 1995-05-10
GB9215633D0 (en) 1992-09-09
TW258663B (en:Method) 1995-10-01

Similar Documents

Publication Publication Date Title
MX9304435A (es) Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
TW283645B (en:Method)
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ZA921538B (en) Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
ES2172654T3 (es) Uso de nsaid para el tratamiento de carcinomas de celulas escamosas de la cavidad oral u orofaringe.
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
PE13197A1 (es) Venlafaxina en el tratamiento de amenorrea hipotalamica en mujeres no deprimidas
NO940266L (no) Indre strålingsskade
MY106067A (en) Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors.
NO900251L (no) Fremgangsmaate for behandling eller hindring av intrinsik aldret hud med retinoider.
AR247984A1 (es) Metodo para la preparacion de una composicion sinergica que tiene actividad antiplaca o antigingivitis
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
IL100874A0 (en) Oxypurine nucleosides and their congeners,and acyl derivatives thereof,for improvement of hematopoiesis
SE8904354D0 (sv) A pharmaceutical composition
EP0037488A3 (en) Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes
FI951511A0 (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
CO4130200A1 (es) Inhibidores de proteasa del hiv utiles en el tratamiento del sida
MX173156B (es) Composiciones para tratar o evitar la placa dental o enfermedades gingivales o periodontales de la cavidad oral en humanos o animales inferiores
MX9400040A (es) Composiciones para tratar trastornos respiratorios.
MX9302985A (es) Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad.
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
UY25103A1 (es) Composición para el tratamiento de diabetes mellitus